IQVIA Holdings Inc. (IQV): Price and Financial Metrics
IQV Price/Volume Stats
Current price | $217.00 | 52-week high | $237.96 |
Prev. close | $214.34 | 52-week low | $167.42 |
Day low | $212.12 | Volume | 984,100 |
Day high | $217.28 | Avg. volume | 1,017,637 |
50-day MA | $218.95 | Dividend yield | N/A |
200-day MA | $209.49 | Market Cap | 39.60B |
IQV Stock Price Chart Interactive Chart >
IQV POWR Grades
- Growth is the dimension where IQV ranks best; there it ranks ahead of 92.3% of US stocks.
- IQV's strongest trending metric is Quality; it's been moving down over the last 26 weeks.
- IQV ranks lowest in Momentum; there it ranks in the 35th percentile.
IQV Stock Summary
- IQVIA HOLDINGS INC's market capitalization of $40,151,825,000 is ahead of 93.57% of US-listed equities.
- IQV's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 425.01 -- higher than 92.15% of US-listed equities with positive expected earnings growth.
- In terms of volatility of its share price, IQV is more volatile than merely 14.32% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to IQVIA HOLDINGS INC are NDAQ, DRI, RYAAY, WTW, and CMG.
- Visit IQV's SEC page to see the company's official filings. To visit the company's web site, go to www.iqvia.com.
IQV Valuation Summary
- IQV's price/earnings ratio is 37.8; this is 29.67% higher than that of the median Healthcare stock.
- IQV's price/sales ratio has moved up 1.7 over the prior 130 months.
Below are key valuation metrics over time for IQV.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
IQV | 2023-12-29 | 2.8 | 7.3 | 37.8 | 27.6 |
IQV | 2023-12-28 | 2.9 | 7.3 | 38.1 | 27.7 |
IQV | 2023-12-27 | 2.8 | 7.3 | 37.9 | 27.7 |
IQV | 2023-12-26 | 2.8 | 7.3 | 37.8 | 27.6 |
IQV | 2023-12-22 | 2.8 | 7.2 | 37.5 | 27.4 |
IQV | 2023-12-21 | 2.8 | 7.2 | 37.5 | 27.4 |
IQV Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at 335.08%.
- Its 2 year revenue growth rate is now at 25.77%.
- The 5 year revenue growth rate now stands at 44.72%.
The table below shows IQV's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 14,410 | 2,260 | 1,091 |
2022-09-30 | 14,307 | 2,392 | 1,182 |
2022-06-30 | 14,136 | 2,373 | 1,160 |
2022-03-31 | 14,033 | 2,583 | 1,079 |
2021-12-31 | 13,874 | 2,942 | 966 |
2021-09-30 | 13,536 | 3,000 | 767 |
IQV's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- IQV has a Quality Grade of C, ranking ahead of 29.06% of graded US stocks.
- IQV's asset turnover comes in at 0.558 -- ranking 289th of 563 Business Services stocks.
- ISSC, MSTR, and TRUE are the stocks whose asset turnover ratios are most correlated with IQV.
The table below shows IQV's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.558 | 0.332 | 0.104 |
2021-06-30 | 0.534 | 0.336 | 0.089 |
2021-03-31 | 0.500 | 0.337 | 0.070 |
2020-12-31 | 0.480 | 0.340 | 0.058 |
2020-09-30 | 0.469 | 0.340 | 0.051 |
2020-06-30 | 0.474 | 0.334 | 0.049 |
IQV Price Target
For more insight on analysts targets of IQV, see our IQV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $200.00 | Average Broker Recommendation | 1.33 (Strong Buy) |
IQVIA Holdings Inc. (IQV) Company Bio
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. IQVIA is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services. It has a network of more than 88,000 employees in more than 100 countries and a market capitalization of $49 Billion as of August 2021. As of 2017, IQVIA was reported to be one of the world's largest contract research organizations. (Source:Wikipedia)
Latest IQV News From Around the Web
Below are the latest news stories about IQVIA HOLDINGS INC that investors may wish to consider to help them evaluate IQV as an investment opportunity.
Should You Be Impressed By IQVIA Holdings Inc.'s (NYSE:IQV) ROE?While some investors are already well versed in financial metrics (hat tip), this article is for those who would like... |
IQVIA Holdings Inc.'s (NYSE:IQV) Intrinsic Value Is Potentially 26% Above Its Share PriceKey Insights The projected fair value for IQVIA Holdings is US$290 based on 2 Stage Free Cash Flow to Equity Current... |
IQVIA Holdings Inc. (NYSE:IQV) Not Lagging Market On Growth Or PricingIQVIA Holdings Inc.'s ( NYSE:IQV ) price-to-earnings (or "P/E") ratio of 37.1x might make it look like a strong sell... |
Investors in IQVIA Holdings (NYSE:IQV) have seen respectable returns of 91% over the past five yearsPassive investing in index funds can generate returns that roughly match the overall market. But in our experience... |
Insiders At IQVIA Holdings Sold US$6.6m In Stock, Alluding To Potential WeaknessIn the last year, many IQVIA Holdings Inc. ( NYSE:IQV ) insiders sold a substantial stake in the company which may have... |
IQV Price Returns
1-mo | -2.14% |
3-mo | 10.73% |
6-mo | -1.29% |
1-year | -7.86% |
3-year | 16.10% |
5-year | 68.47% |
YTD | -6.21% |
2023 | 12.93% |
2022 | -27.38% |
2021 | 57.47% |
2020 | 15.96% |
2019 | 33.00% |
Continue Researching IQV
Here are a few links from around the web to help you further your research on Iqvia Holdings Inc's stock as an investment opportunity:Iqvia Holdings Inc (IQV) Stock Price | Nasdaq
Iqvia Holdings Inc (IQV) Stock Quote, History and News - Yahoo Finance
Iqvia Holdings Inc (IQV) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...